Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus

by Kinjel Shah

LLY, MRK, PFE, ABBV and NVS announce report third-quarter results.

Company News for Oct 31, 2024

by Zacks Equity Research

Companies In The Article Are:SMCI, LLY, ITW, CLH

Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus

by Zacks Equity Research

AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.

Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks

by Zacks Equity Research

Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.

ADP Higher Than Expected

by Zacks Equity Research

ADP Higher Than Expected

Mark Vickery headshot

Goldilocks ADP Jobs Numbers, Q3 GDP and Earnings

by Mark Vickery

ADP private-sector payrolls for October came in at +253K, far ahead of the 113K expected.

Lilly (LLY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Eli Lilly (LLY) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of -22.37% and 4.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?

by Zacks Equity Research

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.

INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

by Zacks Equity Research

Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.

Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings?

by Zacks Equity Research

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.

Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?

by Zacks Equity Research

Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.

Kinjel Shah headshot

Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?

by Kinjel Shah

Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.

Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales

by Zacks Equity Research

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

NVS vs. LLY: Which Stock Is the Better Value Option?

by Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?

Sundeep Ganoria headshot

Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?

by Sundeep Ganoria

Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.

Lilly (LLY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Lilly (LLY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

by Zacks Equity Research

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases

by Zacks Equity Research

Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.

Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?

by Zacks Equity Research

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.

Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024

by Zacks Equity Research

RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.

Kinjel Shah headshot

Is Pfizer's Attractive Valuation Enough to Invest in the Stock?

by Kinjel Shah

PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.